Shares of ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) rose 7.8% on Thursday . The company traded as high as $3.80 and last traded at $3.73. Approximately 1,275,294 shares traded hands during trading, a decline of 71% from the average daily volume of 4,403,517 shares. The stock had previously closed at $3.46.
Analyst Upgrades and Downgrades
IBRX has been the subject of several recent research reports. Piper Sandler cut their price target on ImmunityBio from $6.00 to $4.75 and set a "neutral" rating for the company in a report on Monday, August 19th. EF Hutton Acquisition Co. I upgraded ImmunityBio to a "strong-buy" rating in a research note on Wednesday.
Read Our Latest Stock Report on IBRX
ImmunityBio Stock Performance
The firm has a market capitalization of $2.91 billion, a price-to-earnings ratio of -3.39 and a beta of 1.02. The firm's 50-day moving average price is $3.68 and its two-hundred day moving average price is $5.36.
ImmunityBio (NASDAQ:IBRX - Get Free Report) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.03). The business had revenue of $1.05 million during the quarter, compared to the consensus estimate of $2.53 million. As a group, equities research analysts anticipate that ImmunityBio, Inc. will post -0.86 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of the stock. Bleakley Financial Group LLC bought a new stake in shares of ImmunityBio in the 1st quarter worth about $58,000. Lazard Asset Management LLC grew its stake in ImmunityBio by 102.6% during the first quarter. Lazard Asset Management LLC now owns 13,019 shares of the company's stock worth $68,000 after buying an additional 6,593 shares during the last quarter. Axxcess Wealth Management LLC acquired a new stake in shares of ImmunityBio during the first quarter worth approximately $85,000. Algert Global LLC bought a new position in shares of ImmunityBio in the second quarter valued at approximately $86,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of ImmunityBio by 22.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company's stock worth $99,000 after acquiring an additional 4,545 shares in the last quarter. 8.58% of the stock is currently owned by institutional investors and hedge funds.
ImmunityBio Company Profile
(
Get Free Report)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
Read More
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
